Compositions and methods for treating opioid receptor associated diseases

Patent metadata

Field	Value
Publication number	US-9956187-B2
Application number	US-201515303221-A
Country	US
Kind code	B2
Filing date	Apr 9, 2015
Priority date	Apr 10, 2014
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

The invention relates to dezocine compositions and uses thereof. Specifically, the invention relates to dezocine compositions, including nano-dezocine compositions and methods for preventing or treating opioid receptor associated diseases, including neuropathic pain; addiction, such as opioid or cocaine addiction; and depression.

First claim

What is claimed is:

1. A method for treating an opioid receptor associated addiction in a subject, the method comprising: administering in the form of nanoparticles to said subject a therapeutically effective amount of dezocine or a pharmaceutical composition thereof, wherein the nanoparticle size is less than or equal to 500 nm.

2. The method of claim 1 , wherein the addiction is an addiction to heroin.

3. The method of claim 1 , wherein said opioid receptor is a mu opioid receptor, a kappa receptor, a delta opioid receptor, or a combination thereof.

4. The method of claim 1 , wherein said dezocine treats said addiction by interacting with a norepinephrine transporter (NET), a serotonin transporter (SERT), or a combination thereof.

5. The method of claim 1 , wherein nanoparticle size ranges from about 5 nm to about 100 nm.

6. The method of claim 1 , wherein the method further comprises administering a therapeutically effective amount of ondansetron, naltrexone, naloxone, ketamine, or a combination thereof.

7. The method of claim 1 , wherein the composition is administered orally, intranasally, transmucosally, or by injection.

Assignees

• Univ Pennsylvania

Inventors

• Liu Renyu
• Krug Geoffrey
• Wu Feixiang
• Blendy Julie

Classifications

• A61K9/5138

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/5123

  Organic compounds, e.g. fats, sugars · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/0043

  Nose · CPC title